View printer-friendly version |
<< Back |
Performance In Line with Preliminary Results Announced
SUMMARY
Year-over-year GAAP Operating Income (Loss) and EPS includes a pre-tax non-cash goodwill impairment of
Quarterly results reflect initial impact of COVID-19.
- Amended Debt Covenant and Increased Cash Availability in April
- Fully drew down
$1 billion revolver in quarter and subsequently issued$1.5 billion of Senior Notes - Amended secured debt covenant in credit facility to provide greater flexibility
- Enhanced financial position and further improved already strong balance sheet
- Fully drew down
- Revenue (6.7)%; Organic Revenue (5.4)%
- Underlying revenue growth in the overall business
- Operating Income (180)%; Adjusted Operating Income (AOI) (30)%1
- Initiated cost-reduction strategies at the end of the quarter in response to COVID-19
- EPS of
$(0.80) ; Adjusted EPS of$0.26
“Our hearts go out to everyone who has been impacted by COVID-19, most especially our employees, client partners and customers who have experienced personal and financial hardship," said
"Our financial performance demonstrates the resiliency of Aramark’s flexible business model, as well as our ability to adapt quickly to changing market conditions,” Zillmer added. “The proactive steps we have taken to navigate this difficult economic environment should position the Company to emerge stronger than ever.”
1 Constant Currency. |
SECOND QUARTER RESULTS*
Consolidated Revenue was
- FSS United States experienced interruption primarily within Education, Business & Industry and Sports & Leisure, although most clients maintained operations on a limited basis that included alternative meal programs and services to essential businesses. Healthcare, Facilities and Corrections had relatively stable performance with increased demand across many locations.
FSS International , with its diverse verticals across 18 countries, managed through different stages of the impact from COVID-19 asGermany andSpain were particularly affected due to government imposed shutdowns.China operations have largely recovered and been awarded new contracts based on the business' response to COVID-19 and commitment to client services.- Uniform & Career Apparel service continued for essential businesses with a heightened focus on safe and hygienic needs.
|
Revenue |
|||
|
Q2 '20 |
Q2 '19 |
Change |
Organic Revenue Change |
FSS United States1 |
|
|
(7.7)% |
(7.7)% |
|
853 |
942 |
(9.4)% |
(4.1)% |
Uniform & Career Apparel |
647 |
641 |
0.9% |
1.0% |
|
|
|
(6.7)% |
(5.4)% |
Difference between GAAP Revenue and Organic Revenue reflects the elimination of currency translation. |
Operating Loss of
- FSS United States performance was impacted by COVID-19—especially in Education, Business & Industry, and Sports & Leisure; negative net-new business in Education; as well as planned targeted reinvestment early in the quarter to accelerate longer-term growth that included additional resources for new account sales and client retention efforts.
FSS International was at the forefront of the virus, specifically inChina early in the quarter, with performance then affected by government imposed shutdowns inEurope andCanada , where labor costs tend to be less variable in the near-term due to country-specific labor laws and regulations.- Uniform & Career Apparel was impacted by COVID-19 in addition to personnel costs related to sales growth initiatives, partially offset by solid underlying new business growth and synergies from the AmeriPride acquisition.
- Corporate results reflected a reduction in equity-based compensation expectations resulting from the impact of COVID-19.
|
Operating Income (Loss) |
|
Adjusted Operating Income |
||||||
|
Q2 '20 |
Q2 '19 |
Change |
|
Q2 '20 |
Q2 '19 |
Constant- |
||
FSS United States |
|
|
(4)% |
|
|
|
(39)% |
||
|
(191) |
42 |
(556)% |
|
14 |
44 |
(67)% |
||
Uniform & Career Apparel |
47 |
38 |
22% |
|
59 |
65 |
(9)% |
||
Corporate |
(19) |
(26) |
27% |
|
(3) |
(25) |
88% |
||
|
( |
|
(180)% |
|
|
|
(30)% |
* May not total due to rounding. |
GAAP SUMMARY
GAAP metrics for operating income (loss), net income (loss) attributable to
On a GAAP basis, revenue was
CURRENCY
A stronger
CASH FLOW
CAPITAL STRUCTURE
- Fully drew down the
$1 billion revolving credit facility. - Subsequent to the end of the quarter,
- Issued
$1.5 billion in Senior Unsecured Notes due 2025. - Amended its credit facility to suspend the secured debt ratio covenant requirement for four quarters from the
September 2020 quarter to theJune 2021 quarter—in order to prevent the effects of COVID-19 from distorting the covenant calculations.
- Issued
DIVIDEND DECLARATION
The Company's Board of Directors approved a quarterly dividend of
BUSINESS UPDATE
Given the rapidly changing market dynamics,
As referenced in the preliminary second quarter results released on
The Company is in the process of determining potential future benefits from the 2020 CARES Act stimulus program and the various provisions that will be adopted in the coming quarters. This may include employee retention tax credits, payroll tax deferral, tax credits, NOL carryback modifications and other stimulus measures.
“As we look to the future, the health and safety of our employees and everyone we serve remain paramount. With that in mind, we have developed comprehensive re-opening plans, including new models for service delivery and customer engagement, all designed to ensure the safest, most hygienic environments,” Zillmer added. “I am very encouraged about the opportunities ahead of us.”
CONFERENCE CALL SCHEDULED
The Company has scheduled a conference call at
About
Selected Operational and Financial Metrics
Adjusted Revenue (Organic)
Adjusted Revenue (Organic) represents revenue growth, adjusted to eliminate the effects of material divestitures and the impact of currency translation.
Adjusted Operating Income
Adjusted Operating Income represents operating (loss) income adjusted to eliminate the change in amortization of acquisition-related intangible assets; the impact of the change in fair value related to certain gasoline and diesel agreements; severance and other charges; the effect of divestitures (including the gain on the sale); merger and integration related charges; asset impairments; tax reform related employee reinvestments and other items impacting comparability.
Adjusted Operating Income (Constant Currency)
Adjusted Operating Income (Constant Currency) represents Adjusted Operating Income adjusted to eliminate the impact of currency translation.
Adjusted Net Income
Adjusted Net Income represents net (loss) income attributable to
Adjusted Net Income (Constant Currency)
Adjusted Net Income (Constant Currency) represents Adjusted Net Income adjusted to eliminate the impact of currency translation.
Adjusted EPS
Adjusted EPS represents Adjusted Net Income divided by diluted weighted average shares outstanding.
Adjusted EPS (Constant Currency)
Adjusted EPS (Constant Currency) represents Adjusted EPS adjusted to eliminate the impact of currency translation.
Covenant Adjusted EBITDA
Covenant Adjusted EBITDA represents net income attributable to
Free Cash Flow
Free Cash Flow represents net cash (used in) provided by operating activities less net purchases of property and equipment and other. Management believes that the presentation of free cash flow provides useful information to investors because it represents a measure of cash flow available for distribution among all the security holders of the Company.
We use Adjusted Revenue (Organic), Adjusted Operating Income (including on a constant currency basis), Adjusted Net Income (including on a constant currency basis), Adjusted EPS (including on a constant currency basis), Covenant Adjusted EBITDA and Free Cash Flow as supplemental measures of our operating profitability and to control our cash operating costs. We believe these financial measures are useful to investors because they enable better comparisons of our historical results and allow our investors to evaluate our performance based on the same metrics that we use to evaluate our performance and trends in our results. These financial metrics are not measurements of financial performance under generally accepted accounting principles, or GAAP. Our presentation of these metrics has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. You should not consider these measures as alternatives to revenue, operating income (loss), net income (loss), or earnings (loss) per share, determined in accordance with GAAP. Adjusted Revenue (Organic), Adjusted Operating Income, Adjusted Net Income, Adjusted EPS, Covenant Adjusted EBITDA and Free Cash Flow as presented by us may not be comparable to other similarly titled measures of other companies because not all companies use identical calculations.
Explanatory Notes to the Non-GAAP Schedules
Amortization of Acquisition-Related Intangible Assets - adjustments to eliminate the change in amortization resulting from the purchase accounting applied to the
Severance and Other Charges - adjustments to eliminate severance expenses in the applicable period (
Effect of Divestitures - adjustments to eliminate the impact that the Healthcare Technologies divestiture had on comparative periods.
Merger and Integration Related Charges - adjustments to eliminate merger and integration charges primarily related to the Avendra and AmeriPride acquisitions, including deal costs, costs for transitional employees and integration related consulting costs (
Goodwill Impairment - adjustment to eliminate the impact of a non-cash impairment charge to goodwill.
Gain on sale of Healthcare Technologies - adjustment to eliminate the impact of the gain on sale of the Healthcare Technologies business.
Tax Reform Related Employee Reinvestments - adjustments to eliminate certain reinvestments associated with tax savings created by the Tax Cuts and Jobs Act of 2017, including employee training expenses and retirement contributions (
Gains, Losses and Settlements impacting comparability - adjustments to eliminate certain transactions that are not indicative of our ongoing operational performance, primarily for income/loss from prior years' loss experience under our casualty insurance program (
Effect of Refinancing and Other on Interest and Other Financing Costs, net - adjustments to eliminate expenses associated with refinancing activities undertaken by the Company in the applicable period such as charges related to the payment of a call premium and non-cash charges for the write-offs of unamortized deferred financing costs and debt premiums related to the repayment of the Senior Notes due 2024.
Effect of Tax Legislation on Provision for Income Taxes - adjustments to eliminate the impact of tax legislation that is not indicative of our ongoing tax position based on the new tax policies, including the CARES Act and
Tax Impact Related to Shareholder Transactions - adjustments to eliminate the tax impact of equity award exercises by the Company's former chief executive officer and the tax impact related to cash proceeds received from
Tax Impact of Adjustments to Adjusted Net Income - adjustments to eliminate the net tax impact of the adjustments to adjusted net income calculated based on a blended
Effect of Currency Translation - adjustments to eliminate the impact that fluctuations in currency translation rates had on the comparative results by presenting the periods on a constant currency basis. Assumes constant foreign currency exchange rates based on the rates in effect for the prior year period being used in translation for the comparable current year period.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events and financial performance with respect to, without limitation, conditions in our industry, our operations, our economic performance and financial condition, including, in particular, statements by our CEO and including with respect to, without limitation, the impact of COVID-19 on our business, financial performance and operating results, anticipated effects of our adoption of new accounting standards, the expected impact of strategic portfolio actions, the benefits and costs of our acquisitions of each of
Forward-looking statements speak only as of the date made. All statements we make relating to our estimated and projected earnings, costs, expenditures, cash flows, growth rates, financial results and our estimated benefits and costs of our acquisitions are forward-looking statements. In addition, we, through our senior management, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments. These forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those that we expected. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the cautionary statements. Some of the factors that we believe could affect our results or the costs and benefits of the acquisitions include without limitation: the severity and duration of the COVID-19 pandemic; the pandemic's impact on the
ARAMARK AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME (Unaudited) (In Thousands, Except Per Share Amounts) |
||||||||
|
|
Three Months Ended |
||||||
|
|
|
|
|
||||
Revenue |
|
$ |
3,731,559 |
|
|
$ |
3,999,987 |
|
Costs and Expenses: |
|
|
|
|
||||
Cost of services provided |
|
3,407,589 |
|
|
3,639,959 |
|
||
Depreciation and amortization |
|
147,975 |
|
|
147,908 |
|
||
Selling and general corporate expenses |
|
75,071 |
|
|
88,285 |
|
||
|
|
198,600 |
|
|
— |
|||
Gain on sale of Healthcare Technologies |
|
— |
|
1,000 |
|
|||
|
|
3,829,235 |
|
|
3,877,152 |
|
||
Operating (loss) income |
|
(97,676 |
) |
|
122,835 |
|
||
Interest and Other Financing Costs, net |
|
99,822 |
|
|
84,178 |
|
||
(Loss) Income Before Income Taxes |
|
(197,498 |
) |
|
38,657 |
|
||
Provision for Income Taxes |
|
4,523 |
|
|
9,347 |
|
||
Net (loss) income |
|
(202,021 |
) |
|
29,310 |
|
||
Less: Net income (loss) attributable to noncontrolling interest |
|
239 |
|
|
(43 |
) |
||
Net (loss) income attributable to |
|
$ |
(202,260 |
) |
|
$ |
29,353 |
|
|
|
|
|
|
||||
(Loss) Earnings per share attributable to |
|
|
|
|
||||
Basic |
|
$ |
(0.80 |
) |
|
$ |
0.12 |
|
Diluted |
|
$ |
(0.80 |
) |
|
$ |
0.12 |
|
Weighted Average Shares Outstanding: |
|
|
|
|
||||
Basic |
|
252,354 |
|
|
246,217 |
|
||
Diluted |
|
252,354 |
|
|
250,347 |
|
||
|
|
Six Months Ended |
||||||
|
|
|
|
|
||||
Revenue |
|
$ |
7,985,156 |
|
|
$ |
8,265,336 |
|
Costs and Expenses: |
|
|
|
|
||||
Cost of services provided |
|
7,175,702 |
|
|
7,434,404 |
|
||
Depreciation and amortization |
|
295,911 |
|
|
298,629 |
|
||
Selling and general corporate expenses |
|
158,326 |
|
|
192,415 |
|
||
|
|
198,600 |
|
|
— |
|||
Gain on sale of Healthcare Technologies |
|
— |
|
(156,309 |
) |
|||
|
|
7,828,539 |
|
|
7,769,139 |
|
||
Operating income |
|
156,617 |
|
|
496,197 |
|
||
Interest and Other Financing Costs, net |
|
179,407 |
|
|
167,155 |
|
||
(Loss) Income Before Income Taxes |
|
(22,790 |
) |
|
329,042 |
|
||
Provision for Income Taxes |
|
33,348 |
|
|
49,054 |
|
||
Net (loss) income |
|
(56,138 |
) |
|
279,988 |
|
||
Less: Net income (loss) attributable to noncontrolling interest |
|
361 |
|
|
(49 |
) |
||
Net (loss) income attributable to |
|
$ |
(56,499 |
) |
|
$ |
280,037 |
|
|
|
|
|
|
||||
(Loss) Earnings per share attributable to |
|
|
|
|
||||
Basic |
|
$ |
(0.23 |
) |
|
$ |
1.14 |
|
Diluted |
|
$ |
(0.23 |
) |
|
$ |
1.11 |
|
Weighted Average Shares Outstanding: |
|
|
|
|
||||
Basic |
|
250,543 |
|
|
246,540 |
|
||
Diluted |
|
250,543 |
|
|
251,355 |
|
ARAMARK AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS* |
||||||||
(Unaudited) |
||||||||
(In Thousands) |
||||||||
|
|
|
|
|
||||
|
|
|
|
|
||||
Assets |
|
|
|
|
||||
|
|
|
|
|
||||
Current Assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
1,202,964 |
|
|
$ |
246,643 |
|
Receivables |
|
1,850,980 |
|
|
1,806,964 |
|
||
Inventories |
|
403,799 |
|
|
411,319 |
|
||
Prepayments and other current assets |
|
198,592 |
|
|
193,461 |
|
||
Total current assets |
|
3,656,335 |
|
|
2,658,387 |
|
||
Property and Equipment, net |
|
2,129,306 |
|
|
2,181,762 |
|
||
|
|
5,319,626 |
|
|
5,518,800 |
|
||
Other Intangible Assets |
|
1,986,079 |
|
|
2,033,566 |
|
||
Operating Lease Right-of-use Assets |
|
579,719 |
|
|
— |
|
||
Other Assets |
|
1,176,433 |
|
|
1,343,806 |
|
||
|
|
$ |
14,847,498 |
|
|
$ |
13,736,321 |
|
|
|
|
|
|
||||
Liabilities and Stockholders' Equity |
|
|
|
|
||||
|
|
|
|
|
||||
Current Liabilities: |
|
|
|
|
||||
Current maturities of long-term borrowings |
|
$ |
103,406 |
|
|
$ |
69,928 |
|
Current operating lease liabilities |
|
75,705 |
|
|
— |
|
||
Accounts payable |
|
793,464 |
|
|
999,517 |
|
||
Accrued expenses and other current liabilities |
|
1,325,282 |
|
|
1,635,853 |
|
||
Total current liabilities |
|
2,297,857 |
|
|
2,705,298 |
|
||
Long-Term Borrowings |
|
7,862,587 |
|
|
6,612,239 |
|
||
Noncurrent Operating Lease Liabilities |
|
354,833 |
|
|
— |
|
||
Deferred Income Taxes and Other Noncurrent Liabilities |
|
1,152,550 |
|
|
1,088,822 |
|
||
Redeemable Noncontrolling Interest |
|
10,226 |
|
|
9,915 |
|
||
Total Stockholders' Equity |
|
3,169,445 |
|
|
3,320,047 |
|
||
|
|
$ |
14,847,498 |
|
|
$ |
13,736,321 |
|
*In connection with the Company's adoption of ASC 842, Leases, three new line items were added to the balance sheet to reflect the recording of operating lease liabilities (current and noncurrent), offset by operating lease right-of-use assets. Further details will be available in the Quarterly Report on Form 10-Q for the quarterly period ended |
ARAMARK AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(Unaudited) |
||||||||
(In Thousands) |
||||||||
|
|
|
|
|
||||
|
|
|
|
|
||||
|
|
Six Months Ended |
||||||
|
|
|
|
|
||||
Cash flows from operating activities: |
|
|
|
|
||||
Net (loss) income |
|
$ |
(56,138 |
) |
|
$ |
279,988 |
|
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities |
|
|
|
|
||||
Depreciation and amortization |
|
295,911 |
|
|
298,629 |
|
||
|
|
198,600 |
|
|
— |
|||
Deferred income taxes |
|
17,405 |
|
|
3,475 |
|
||
Share-based compensation expense |
|
4,259 |
|
|
33,241 |
|
||
Net gain on sale of Healthcare Technologies |
|
— |
|
(139,165 |
) |
|||
Changes in operating assets and liabilities |
|
(597,726 |
) |
|
(361,168 |
) |
||
Payments made to clients on contracts |
|
(26,355 |
) |
|
(26,551 |
) |
||
Other operating activities |
|
72,418 |
|
|
534 |
|
||
Net cash (used in) provided by operating activities |
|
(91,626 |
) |
|
88,983 |
|
||
|
|
|
|
|
||||
Cash flows from investing activities: |
|
|
|
|
||||
Net purchases of property and equipment and other |
|
(205,331 |
) |
|
(222,846 |
) |
||
Acquisitions, divestitures and other investing activities |
|
8,743 |
|
|
281,041 |
|
||
Net cash (used in) provided by investing activities |
|
(196,588 |
) |
|
58,195 |
|
||
|
|
|
|
|
||||
Cash flows from financing activities: |
|
|
|
|
||||
Net proceeds/payments of long-term borrowings |
|
887,697 |
|
|
(245,387 |
) |
||
Net change in funding under the Receivables Facility |
|
400,000 |
|
|
205,000 |
|
||
Payments of dividends |
|
(55,257 |
) |
|
(54,220 |
) |
||
Proceeds from issuance of common stock |
|
85,048 |
|
|
10,372 |
|
||
Repurchase of common stock |
|
(6,540 |
) |
|
(50,000 |
) |
||
Other financing activities |
|
(65,658 |
) |
|
(29,120 |
) |
||
Net cash provided by (used in) financing activities |
|
1,245,290 |
|
|
(163,355 |
) |
||
Effect of foreign exchange rates on cash and cash equivalents |
|
(755 |
) |
|
(3,461 |
) |
||
Increase (decrease) in cash and cash equivalents |
|
956,321 |
|
|
(19,638 |
) |
||
Cash and cash equivalents, beginning of period |
|
246,643 |
|
|
215,025 |
|
||
Cash and cash equivalents, end of period |
|
$ |
1,202,964 |
|
|
$ |
195,387 |
|
ARAMARK AND SUBSIDIARIES |
||||||||||||||||||||
RECONCILIATION OF NON-GAAP MEASURES |
||||||||||||||||||||
ADJUSTED CONSOLIDATED OPERATING INCOME MARGIN |
||||||||||||||||||||
(Unaudited) |
||||||||||||||||||||
(In thousands) |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Three Months Ended |
||||||||||||||||||
|
|
|
||||||||||||||||||
|
|
FSS United States |
|
|
|
Uniform |
|
Corporate |
|
Subsidiaries |
||||||||||
Revenue (as reported) |
|
$ |
2,231,107 |
|
|
$ |
853,448 |
|
|
$ |
647,004 |
|
|
|
|
$ |
3,731,559 |
|
||
Operating Income (Loss) (as reported) |
|
$ |
65,791 |
|
|
$ |
(191,179) |
|
|
$ |
46,747 |
|
|
$ |
(19,035) |
|
|
$ |
(97,676) |
|
Operating Income (Loss) Margin (as reported) |
|
2.95 |
% |
|
(22.40) |
% |
|
7.23 |
% |
|
|
|
(2.62) |
% |
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Revenue (as reported) |
|
$ |
2,231,107 |
|
|
$ |
853,448 |
|
|
$ |
647,004 |
|
|
|
|
$ |
3,731,559 |
|
||
Effect of Currency Translation |
|
105 |
|
|
50,236 |
|
|
352 |
|
|
|
|
50,693 |
|
||||||
Adjusted Revenue (Organic) |
|
$ |
2,231,212 |
|
|
$ |
903,684 |
|
|
$ |
647,356 |
|
|
|
|
$ |
3,782,252 |
|
||
Revenue Growth (as reported) |
|
(7.69) |
% |
|
(9.41) |
% |
|
0.94 |
% |
|
|
|
(6.71) |
% |
||||||
Adjusted Revenue Growth (Organic) |
|
(7.69) |
% |
|
(4.07) |
% |
|
1.00 |
% |
|
|
|
(5.44) |
% |
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating Income (Loss) (as reported) |
|
$ |
65,791 |
|
|
$ |
(191,179) |
|
|
$ |
46,747 |
|
|
$ |
(19,035) |
|
|
$ |
(97,676) |
|
Amortization of Acquisition-Related Intangible Assets |
|
21,262 |
|
|
1,669 |
|
|
6,194 |
|
|
— |
|
|
29,125 |
|
|||||
Severance and Other Charges |
|
— |
|
|
3,647 |
|
|
— |
|
|
3,247 |
|
|
6,894 |
|
|||||
Merger and Integration Related Charges |
|
947 |
|
|
165 |
|
|
6,190 |
|
|
— |
|
|
7,302 |
|
|||||
Goodwill Impairment |
|
— |
|
|
198,600 |
|
|
— |
|
|
— |
|
|
198,600 |
|
|||||
Gains, Losses and Settlements impacting comparability |
|
5,828 |
|
|
1,111 |
|
|
— |
|
|
12,899 |
|
|
19,838 |
|
|||||
Adjusted Operating Income |
|
$ |
93,828 |
|
|
$ |
14,013 |
|
|
$ |
59,131 |
|
|
$ |
(2,889) |
|
|
$ |
164,083 |
|
Effect of Currency Translation |
|
(92) |
|
|
429 |
|
|
(1) |
|
|
— |
|
|
336 |
|
|||||
Adjusted Operating Income (Constant Currency) |
|
$ |
93,736 |
|
|
$ |
14,442 |
|
|
$ |
59,130 |
|
|
$ |
(2,889) |
|
|
$ |
164,419 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating Income Growth (as reported) |
|
(4.39) |
% |
|
(556.29) |
% |
|
22.38 |
% |
|
27.00 |
% |
|
(179.52) |
% |
|||||
Adjusted Operating Income Growth |
|
(38.49) |
% |
|
(68.10) |
% |
|
(8.53) |
% |
|
88.35 |
% |
|
(30.57) |
% |
|||||
Adjusted Operating Income Growth (Constant Currency) |
|
(38.55) |
% |
|
(67.13) |
% |
|
(8.54) |
% |
|
88.35 |
% |
|
(30.43) |
% |
|||||
Adjusted Operating Income Margin (Constant Currency) |
|
4.20 |
% |
|
1.60 |
% |
|
9.13 |
% |
|
|
|
4.35 |
% |
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Three Months Ended |
||||||||||||||||||
|
|
|
||||||||||||||||||
|
|
FSS United States |
|
|
|
Uniform |
|
Corporate |
|
Subsidiaries |
||||||||||
Revenue (as reported) |
|
$ |
2,416,958 |
|
|
$ |
942,063 |
|
|
$ |
640,966 |
|
|
|
|
$ |
3,999,987 |
|
||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating Income (as reported) |
|
$ |
68,815 |
|
|
$ |
41,899 |
|
|
$ |
38,198 |
|
|
$ |
(26,077) |
|
|
$ |
122,835 |
|
Amortization of Acquisition-Related Intangible Assets |
|
21,184 |
|
|
1,358 |
|
|
6,115 |
|
|
— |
|
|
28,657 |
|
|||||
Severance and Other Charges |
|
3,992 |
|
|
— |
|
|
— |
|
|
4,418 |
|
|
8,410 |
|
|||||
Merger and Integration Related Charges |
|
1,186 |
|
|
— |
|
|
8,477 |
|
|
— |
|
|
9,663 |
|
|||||
Gain on sale of Healthcare Technologies |
|
1,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
1,000 |
|
|||||
Tax Reform Related Employee Reinvestments |
|
51,802 |
|
|
352 |
|
|
11,858 |
|
|
1,443 |
|
|
65,455 |
|
|||||
Gains, Losses and Settlements impacting comparability |
|
4,567 |
|
|
323 |
|
|
— |
|
|
(4,579) |
|
|
311 |
|
|||||
Adjusted Operating Income |
|
$ |
152,546 |
|
|
$ |
43,932 |
|
|
$ |
64,648 |
|
|
$ |
(24,795) |
|
|
$ |
236,331 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating Income Margin (as reported) |
|
2.85 |
% |
|
4.45 |
% |
|
5.96 |
% |
|
|
|
3.07 |
% |
||||||
Adjusted Operating Income Margin |
|
6.31 |
% |
|
4.66 |
% |
|
10.09 |
% |
|
|
|
5.91 |
% |
||||||
ARAMARK AND SUBSIDIARIES |
||||||||||||||||||||
RECONCILIATION OF NON-GAAP MEASURES |
||||||||||||||||||||
ADJUSTED CONSOLIDATED OPERATING INCOME MARGIN |
||||||||||||||||||||
(Unaudited) |
||||||||||||||||||||
(In thousands) |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Six Months Ended |
||||||||||||||||||
|
|
|
||||||||||||||||||
|
|
FSS United States |
|
|
|
Uniform |
|
Corporate |
|
Subsidiaries |
||||||||||
Revenue (as reported) |
|
$ |
4,870,067 |
|
|
$ |
1,799,642 |
|
|
$ |
1,315,447 |
|
|
|
|
$ |
7,985,156 |
|
||
Operating Income (Loss) (as reported) |
|
$ |
251,745 |
|
|
$ |
(147,503) |
|
|
$ |
100,057 |
|
|
$ |
(47,682) |
|
|
$ |
156,617 |
|
Operating Income (Loss) Margin (as reported) |
|
5.17 |
% |
|
(8.20) |
% |
|
7.61 |
% |
|
|
|
1.96 |
% |
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Revenue (as reported) |
|
$ |
4,870,067 |
|
|
$ |
1,799,642 |
|
|
$ |
1,315,447 |
|
|
|
|
$ |
7,985,156 |
|
||
Effect of Currency Translation |
|
117 |
|
|
87,629 |
|
|
304 |
|
|
|
|
88,050 |
|
||||||
Adjusted Revenue (Organic) |
|
$ |
4,870,184 |
|
|
$ |
1,887,271 |
|
|
$ |
1,315,751 |
|
|
|
|
$ |
8,073,206 |
|
||
Revenue Growth (as reported) |
|
(4.08) |
% |
|
(5.04) |
% |
|
1.75 |
% |
|
|
|
(3.39) |
% |
||||||
Adjusted Revenue Growth (Organic) |
|
(3.25) |
% |
|
(0.42) |
% |
|
1.77 |
% |
|
|
|
(1.81) |
% |
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating Income (Loss) (as reported) |
|
$ |
251,745 |
|
|
$ |
(147,503) |
|
|
$ |
100,057 |
|
|
$ |
(47,682) |
|
|
$ |
156,617 |
|
Amortization of Acquisition-Related Intangible Assets |
|
42,516 |
|
|
3,327 |
|
|
12,348 |
|
|
— |
|
|
58,191 |
|
|||||
Severance and Other Charges |
|
— |
|
|
3,647 |
|
|
— |
|
|
3,247 |
|
|
6,894 |
|
|||||
Merger and Integration Related Charges |
|
3,311 |
|
|
394 |
|
|
13,661 |
|
|
— |
|
|
17,366 |
|
|||||
Goodwill Impairment |
|
— |
|
|
198,600 |
|
|
— |
|
|
— |
|
|
198,600 |
|
|||||
Tax Reform Related Employee Reinvestments |
|
1,436 |
|
|
— |
|
|
(13) |
|
|
— |
|
|
1,423 |
|
|||||
Gains, Losses and Settlements impacting comparability |
|
(1,295) |
|
|
1,111 |
|
|
74 |
|
|
10,890 |
|
|
10,780 |
|
|||||
Adjusted Operating Income |
|
$ |
297,713 |
|
|
$ |
59,576 |
|
|
$ |
126,127 |
|
|
$ |
(33,545) |
|
|
$ |
449,871 |
|
Effect of Currency Translation |
|
(66) |
|
|
1,587 |
|
|
(21) |
|
|
— |
|
|
1,500 |
|
|||||
Adjusted Operating Income (Constant Currency) |
|
$ |
297,647 |
|
|
$ |
61,163 |
|
|
$ |
126,106 |
|
|
$ |
(33,545) |
|
|
$ |
451,371 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating Income Growth (as reported) |
|
(41.80) |
% |
|
(376.46) |
% |
|
10.08 |
% |
|
40.85 |
% |
|
(68.44) |
% |
|||||
Adjusted Operating Income Growth |
|
(21.74) |
% |
|
(22.31) |
% |
|
(3.25) |
% |
|
42.64 |
% |
|
(14.96) |
% |
|||||
Adjusted Operating Income Growth (Constant Currency) |
|
(21.76) |
% |
|
(20.24) |
% |
|
(3.27) |
% |
|
42.64 |
% |
|
(14.68) |
% |
|||||
Adjusted Operating Income Margin (Constant Currency) |
|
6.11 |
% |
|
3.24 |
% |
|
9.58 |
% |
|
|
|
5.59 |
% |
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Six Months Ended |
||||||||||||||||||
|
|
|
||||||||||||||||||
|
|
FSS United States |
|
|
|
Uniform |
|
Corporate |
|
Subsidiaries |
||||||||||
Revenue (as reported) |
|
$ |
5,077,315 |
|
|
$ |
1,895,183 |
|
|
$ |
1,292,838 |
|
|
|
|
$ |
8,265,336 |
|
||
Effect of Divestitures |
|
(43,680) |
|
|
— |
|
|
— |
|
|
|
|
(43,680) |
|
||||||
Adjusted Revenue (Organic) |
|
$ |
5,033,635 |
|
|
$ |
1,895,183 |
|
|
$ |
1,292,838 |
|
|
|
|
$ |
8,221,656 |
|
||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating Income (as reported) |
|
$ |
432,566 |
|
|
$ |
53,355 |
|
|
$ |
90,892 |
|
|
$ |
(80,616) |
|
|
$ |
496,197 |
|
Amortization of Acquisition-Related Intangible Assets |
|
44,428 |
|
|
2,488 |
|
|
12,134 |
|
|
— |
|
|
59,050 |
|
|||||
Severance and Other Charges |
|
13,947 |
|
|
17,945 |
|
|
493 |
|
|
10,253 |
|
|
42,638 |
|
|||||
Effect of Divestitures |
|
(4,003) |
|
|
— |
|
|
— |
|
|
— |
|
|
(4,003) |
|
|||||
Merger and Integration Related Charges |
|
3,282 |
|
|
— |
|
|
14,990 |
|
|
8 |
|
|
18,280 |
|
|||||
Gain on sale of Healthcare Technologies |
|
(156,309) |
|
|
— |
|
|
— |
|
|
— |
|
|
(156,309) |
|
|||||
Tax Reform Related Employee Reinvestments |
|
51,802 |
|
|
352 |
|
|
11,858 |
|
|
1,443 |
|
|
65,455 |
|
|||||
Gains, Losses and Settlements impacting comparability |
|
(5,276) |
|
|
2,542 |
|
|
— |
|
|
10,431 |
|
|
7,697 |
|
|||||
Adjusted Operating Income |
|
$ |
380,437 |
|
|
$ |
76,682 |
|
|
$ |
130,367 |
|
|
$ |
(58,481) |
|
|
$ |
529,005 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating Income Margin (as reported) |
|
8.52 |
% |
|
2.82 |
% |
|
7.03 |
% |
|
|
|
6.00 |
% |
||||||
Adjusted Operating Income Margin |
|
7.56 |
% |
|
4.05 |
% |
|
10.08 |
% |
|
|
|
6.43 |
% |
ARAMARK AND SUBSIDIARIES |
|||||||||||||||||
RECONCILIATION OF NON-GAAP MEASURES |
|||||||||||||||||
ADJUSTED NET INCOME & ADJUSTED EPS |
|||||||||||||||||
(Unaudited) |
|||||||||||||||||
(In thousands, except per share amounts) |
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
Net (Loss) Income Attributable to Aramark Stockholders (as reported) |
|
$ |
(202,260 |
) |
|
$ |
29,353 |
|
|
$ |
(56,499 |
) |
|
$ |
280,037 |
|
|
|
Adjustment: |
|
|
|
|
|
|
|
|
||||||||
|
Amortization of Acquisition-Related Intangible Assets |
|
29,125 |
|
|
28,657 |
|
|
58,191 |
|
|
59,050 |
|
||||
|
Severance and Other Charges |
|
6,894 |
|
|
8,410 |
|
|
6,894 |
|
|
42,638 |
|
||||
|
Effect of Divestitures |
|
— |
|
— |
|
— |
|
(4,003 |
) |
|||||||
|
Merger and Integration Related Charges |
|
7,302 |
|
|
9,663 |
|
|
17,366 |
|
|
18,280 |
|
||||
|
Goodwill Impairment |
|
198,600 |
|
|
— |
|
198,600 |
|
|
— |
||||||
|
Gain on sale of Healthcare Technologies |
|
— |
|
1,000 |
|
|
— |
|
(156,309 |
) |
||||||
|
Tax Reform Related Employee Reinvestments |
|
— |
|
65,455 |
|
|
1,423 |
|
|
65,455 |
|
|||||
|
Gains, Losses and Settlements impacting comparability |
|
19,838 |
|
|
311 |
|
|
10,780 |
|
|
7,697 |
|
||||
|
Effect of Refinancing and Other on Interest and Other Financing Costs, net |
|
20,883 |
|
|
— |
|
20,883 |
|
|
— |
||||||
|
Effect of Tax Legislation on Provision for Income Taxes |
|
3,685 |
|
|
(809 |
) |
|
3,685 |
|
|
(12,126 |
) |
||||
|
Tax Impact Related to Shareholder Transactions |
|
(6,206 |
) |
|
— |
|
(18,722 |
) |
|
— |
||||||
|
Tax Impact of Adjustments to Adjusted Net Income |
|
(12,874 |
) |
|
(29,240 |
) |
|
(20,898 |
) |
|
(31,342 |
) |
||||
Adjusted Net Income |
|
$ |
64,987 |
|
|
$ |
112,800 |
|
|
$ |
221,703 |
|
|
$ |
269,377 |
|
|
|
Effect of Currency Translation, net of Tax |
|
(105 |
) |
|
— |
|
513 |
|
|
— |
||||||
Adjusted Net Income (Constant Currency) |
|
$ |
64,882 |
|
|
$ |
112,800 |
|
|
$ |
222,216 |
|
|
$ |
269,377 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
(Loss) Earnings Per Share (as reported) |
|
|
|
|
|
|
|
|
|||||||||
|
Net (Loss) Income Attributable to Aramark Stockholders (as reported) |
|
$ |
(202,260 |
) |
|
$ |
29,353 |
|
|
$ |
(56,499 |
) |
|
$ |
280,037 |
|
|
Diluted Weighted Average Shares Outstanding |
|
252,354 |
|
|
250,347 |
|
|
250,543 |
|
|
251,355 |
|
||||
|
|
|
$ |
(0.80 |
) |
|
$ |
0.12 |
|
|
$ |
(0.23 |
) |
|
$ |
1.11 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted Earnings Per Share |
|
|
|
|
|
|
|
|
|||||||||
|
Adjusted Net Income |
|
$ |
64,987 |
|
|
$ |
112,800 |
|
|
$ |
221,703 |
|
|
$ |
269,377 |
|
|
Diluted Weighted Average Shares Outstanding |
|
254,443 |
|
|
250,347 |
|
|
254,294 |
|
|
251,355 |
|
||||
|
|
|
$ |
0.26 |
|
|
$ |
0.45 |
|
|
$ |
0.87 |
|
|
$ |
1.07 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted Earnings Per Share (Constant Currency) |
|
|
|
|
|
|
|
|
|||||||||
|
Adjusted Net Income (Constant Currency) |
|
$ |
64,882 |
|
|
$ |
112,800 |
|
|
$ |
222,216 |
|
|
$ |
269,377 |
|
|
Diluted Weighted Average Shares Outstanding |
|
254,443 |
|
|
250,347 |
|
|
254,294 |
|
|
251,355 |
|
||||
|
|
|
$ |
0.25 |
|
|
$ |
0.45 |
|
|
$ |
0.87 |
|
|
$ |
1.07 |
|
ARAMARK AND SUBSIDIARIES |
|||||||||
RECONCILIATION OF NON-GAAP MEASURES |
|||||||||
NET DEBT TO COVENANT ADJUSTED EBITDA |
|||||||||
(Unaudited) |
|||||||||
(In thousands) |
|||||||||
|
|
|
|
|
|
||||
|
|
|
Twelve Months Ended |
||||||
|
|
|
|
|
|
||||
|
|
|
|
|
|
||||
Net Income Attributable to Aramark Stockholders (as reported) |
|
$ |
112,015 |
|
|
$ |
528,067 |
|
|
|
Interest and Other Financing Costs, net |
|
347,238 |
|
|
350,964 |
|
||
|
Provision for Income Taxes |
|
91,999 |
|
|
87,568 |
|
||
|
Depreciation and Amortization |
|
589,855 |
|
|
608,098 |
|
||
|
Share-based compensation expense(1) |
|
26,297 |
|
|
88,007 |
|
||
|
Unusual or non-recurring (gains) and losses(2) |
|
198,600 |
|
|
(156,309) |
|
||
|
Pro forma EBITDA for equity method investees(3) |
|
6,657 |
|
|
13,197 |
|
||
|
Pro forma EBITDA for certain transactions(4) |
|
15,692 |
|
|
(11,055) |
|
||
|
Other(5) |
|
204,002 |
|
|
185,799 |
|
||
Covenant Adjusted EBITDA |
|
$ |
1,592,355 |
|
|
$ |
1,694,336 |
|
|
|
|
|
|
|
|||||
Net Debt to Covenant Adjusted EBITDA |
|
|
|
|
|||||
|
Total Long-Term Borrowings |
|
$ |
7,965,993 |
|
|
$ |
7,190,625 |
|
|
Less: Cash and cash equivalents |
|
1,202,964 |
|
|
195,387 |
|
||
|
Net Debt |
|
$ |
6,763,029 |
|
|
$ |
6,995,238 |
|
|
Covenant Adjusted EBITDA |
|
$ |
1,592,355 |
|
|
$ |
1,694,336 |
|
|
Net Debt/Covenant Adjusted EBITDA |
|
4.2 |
|
|
4.1 |
|
(1) Represents compensation expense related to the Company's issuances of share-based awards. |
(2) Represents non-cash impairment charge related to goodwill. |
(3) Represents our estimated share of EBITDA primarily from our |
(4) Represents the annualizing of net EBITDA from certain acquisitions and divestitures made during the period. |
(5) "Other" for the twelve months ended |
ARAMARK AND SUBSIDIARIES |
|||||||
RECONCILIATION OF NON-GAAP MEASURES |
|||||||
FREE CASH FLOW |
|||||||
(Unaudited) |
|||||||
(In thousands) |
|||||||
|
|
|
|
||||
|
Six Months Ended |
||||||
|
|
|
|
||||
|
$ |
(91,626 |
) |
|
$ |
88,983 |
|
|
|
|
|
||||
Net purchases of property and equipment and other |
(205,331 |
) |
|
(222,846 |
) |
||
|
|
|
|
||||
Free Cash Flow |
$ |
(296,957 |
) |
|
$ |
(133,863 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005480/en/
Media Inquiries:
(215) 238-4063
Cutler-Karen@aramark.com
Investor Inquiries:
(215) 409-7287
Kissell-Felise@aramark.com
Source: